Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23924412 | 0.90 | KDM4E (0.38) | TACR1TRPV1 | |
| SCHEMBL23924411 | 0.90 | KDM4E (0.38) | TACR1TRPV1 | |
| SCHEMBL23951633 | 0.89 | TACR1 (0.52) | TACR1TRPV1RORCMAPT | |
| SCHEMBL29900665 | 0.88 | TRPV1 (0.39) | TRPV1KCNH2 | |
| SCHEMBL23924227 | 0.84 | KDM4E (0.47) | TACR1TRPV1RORC | |
| SCHEMBL23924337 | 0.84 | KDM4E (0.47) | TACR1TRPV1RORC | |
| SCHEMBL23951339 | 0.83 | KCNH2 (0.54) | TRPV1KCNH2PARP1 | |
| Hydrochloric Acid SCHEMBL23924251 | 0.82 | KCNH2 (0.53) | TRPV1KCNH2PARP1 | |
| Hydrochloric Acid SCHEMBL30098491 | 0.82 | KCNH2 (0.53) | TRPV1KCNH2PARP1 | |
| SCHEMBL23951570 | 0.80 | TACR1 (0.51) | TACR1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | TACR1 3676/4885PROKR1 4550/4885TRPV1 4072/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | TACR1 3676/4885PROKR1 4550/4885TRPV1 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.